Lapatinib (Tyverb®)

Assessment Status Assessment process complete
Drug Lapatinib
Brand Tyverb®
Indication For the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.
Assessment Process
Full pharmacoeconomic assessment commissioned by HSE 03/12/2007
NCPE assessment completed 28/01/2008
NCPE assessment outcome Reimbursement recommended.

Lapatinib could be considered cost-effective in Ireland. However in view of the uncertainty surrounding the ICER, we (NCPE) suggest conditional reimbursement under the High Tech Drugs scheme.

Technical Summary